Mount Vernon Cancer Network has a population of 1.3m residents. It encompasses NHS Hertfordshire, NHS Luton and southern part of NHS Bedfordshire and Provider Trusts: North: East of England SHA, West: North Luton and Bedfordshire Foundation Trust.

In line with the Cancer Reform Strategy’s recommendations, Mount Vernon Cancer Network and its constituent Lung Cancer Tumour Site Specialised Group (TSSG) have reviewed various sources of information since 2008 to ascertain where the network was ranked in terms of outcomes and aspects of service delivery. These sources included:

1. eAtlas survival data
2. Cancer Commissioning Tool kit
3. National Lung Cancer Audit*2

These indicated that the network was in the 4th quartile for certain measures and highlighted the need for further in-depth review of information pertaining to lung cancer service provision such as diagnoses rates, staging and active treatment rates.

Within the working with the local cancer registry, Eastern Cancer Registration and Information Centre (ECRC). The network has been able to review more up to date data for the registered lung cancer population over the time period 2007 to 2008.

Mount Vernon Cancer Network has a lower than average incidence rate of 51.8 per 100,000 in 2005, and a ranked 13th in terms of network according to the highest number of cases with the primary cancer located in either the trachea, bronchus and lung (C33-34).

A review of relative 1-year survival rates in lung cancer indicates Mount Vernon Cancer Network has a significantly lower overall rate of 55.7% (95% confidence interval 54.2, 57.2%) and is in the 4th quartile when compared to the other 33 English Cancer Networks.


A NETWORK’S EXPERIENCE OF USING DATA TO BETTER UNDERSTAND VARIANCE AND IMPROVE OUTCOMES IN LUNG CANCER

Dr Ivan Trotman;* Dr She Lok;3 Dr David Greenberg;* Andy Murphy;* and Dr Linda McNamara*

*Medical Director and 3Chair Lung Cancer Tumour Site Specialised Group, Mount Vernon Cancer Network; 2Senior Analyst and 3Registry Information Liaison Manager, ECRC (Eastern Cancer Registration and Information Centre), and 2Strategic NHS Cancer Intelligence Manager, Roche Products Ltd.